Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trimer 4571 vaccine + alum
- Development stage
- Unknown
- Lead developer
- National Institutes of Health
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
Trimer 4571 vaccine + alum is an investigational HIV vaccine designed to stimulate the development of broadly neutralizing antibodies (bnAbs) against HIV. It consists of Trimer 4571 (BG505 DS-SOSIP.664), a prefusion-closed stabilized HIV-1 Env trimer, adjuvanted with aluminum hydroxide (alum) to enhance immune response. The vaccine aims to help the immune system produce broadly neutralizing antibodies that can recognize and block many types of HIV from entering healthy cells and may also activate other immune cells to help destroy HIV-infected cells.
- Other names
- Trimer 4571 vaccine with alumTrimer4571 vaccine with alumTrimer-4571 vaccine with alumBG505 DS-SOSIP.664 with aluminum hydroxideBG-505 DS-SOSIP.664 with aluminum hydroxideBG 505 DS-SOSIP.664 with aluminum hydroxide
02
Targets
BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)
Beyond the preview
Go deeper on Trimer 4571 vaccine + alum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trimer 4571 vaccine + alum.